Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tecovirimat Resistance in Mpox Patients, United States, 2022–2023

27 Oct 2023

Abstract excerpt

During the 2022 multinational outbreak of monkeypox virus (MPXV) infection, the antiviral drug tecovirimat (TPOXX; SIGA Technologies, Inc., https://www.siga.com) was deployed in the United States on a large scale for the first time. The MPXV F13L gene homologue encodes the target of tecovirimat, and single amino acid changes in F13 are known to cause resistance to tecovirimat. Genomic sequencing identified 11...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacillus and Francisella bacterial research
Share to Herpesvirus Infections and Treatments
Share to Poxvirus research and outbreaks

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37856204
DOI: 10.3201/eid2912.231146

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tecovirimat Resistance in Mpox Patients, United States, 2022–2023PMID 37856204Read ↗

Resistance to anti-orthopoxviral drug tecovirimat (TPOXX<sup>®</sup>) during the 2022 mpox outbreak in the USSemantic proximity Read ↗

Notes from the Field: Mpox Cluster Caused by Tecovirimat-Resistant Monkeypox Virus - Five States, October 2023-February 2024.Semantic proximity Read ↗

Prolonged viral shedding in an immunocompromised Korean patient infected with hMPXV, sub-lineage B.1.3, with acquired drug resistant mutations during tecovirimat treatmentSemantic proximity Read ↗

Monkeypox Virus Shedding Despite Tecovirimat Treatment in a Cohort in Toronto, Canada.Semantic proximity Read ↗

Prolonged viral shedding in an immunocompromised Korean patient infected with hMPXV, sub-lineage B.1.3, with acquired drug resistant mutations during tecovirimat treatment.Semantic proximity Read ↗

Tecovirimat is highly efficient on the Monkeypox virus lineage responsible for the international 2022 outbreakSemantic proximity Read ↗

Mechanisms of Tecovirimat Antiviral Activity and Poxvirus ResistanceSemantic proximity Read ↗

Structural insights into tecovirimat antiviral activity and poxvirus resistance.Semantic proximity Read ↗

A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox OutbreakSemantic proximity Read ↗

Repurposing Drugs for Synergistic Combination Therapies to Counteract Monkeypox Virus Tecovirimat ResistanceSemantic proximity Read ↗

Mpox in the Post-2022 Era: A Comprehensive Review of Viral Evolution, Host Adaptation, and Clinical ManagementSemantic proximity Read ↗

Potential therapeutic targets for Mpox: the evidence to dateSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.